Company Hemispherx BioPharma, Inc Nyse

Equities

US42366C3016

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

USD in Million	2022	Weight	2023	Weight	Delta
Ampligen and Other Drugs 100.0 %	0	100.0 %	0	100.0 %	+43.26%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	+43.26%

Managers	Title	Age	Since
Thomas Equels CEO	Chief Executive Officer	71	08-11-16
Robert Dickey DFI	Director of Finance/CFO	68	22-04-03
Christopher McAleer CTO	Chief Tech/Sci/R&D Officer	-	22-05-31
Peter Rodino COO	Chief Operating Officer	72	13-07-22
David R. Strayer CTO	Chief Tech/Sci/R&D Officer	78	85-12-31
Jenene Thomas IRC	Investor Relations Contact	52	-

Members of the board	Title	Age	Since
Nancy K. Bryan BRD	Director/Board Member	66	23-03-27
William Mitchell CHM	Chairman	89	98-06-30
Thomas Equels CEO	Chief Executive Officer	71	08-11-16
Peter Rodino COO	Chief Operating Officer	72	13-07-22
Stewart Appelrouth BRD	Director/Board Member	70	16-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,901,177	45,415,144 ( 91.01 %)	0	91.01 %
Stock B	0	689	0	0

Name	Equities	%	Valuation
Vanguard Global Advisers LLC 4.072 %	1,988,704	4.072 %	936 680 $
Todd Deutsch 3.514 %	1,716,100	3.514 %	808 283 $
Ted D Kellner 3.057 %	1,493,000	3.057 %	703 203 $
Thomas Equels 1.467 %	716,455	1.467 %	337 450 $
BlackRock Institutional Trust Co. NA 1.449 %	707,806	1.449 %	333 377 $
Geode Capital Management LLC 0.7200 %	351,657	0.7200 %	165 630 $
Stewart Appelrouth 0.4909 %	239,765	0.4909 %	112 929 $
Renaissance Technologies LLC 0.4136 %	202,008	0.4136 %	95 146 $
Peter Rodino 0.3721 %	181,718	0.3721 %	85 589 $
STATE STREET CORPORATION 0.3544 %	173,103	0.3544 %	81 532 $

AIM ImmunoTech, Inc.

2117 SW Highway 484

34473, Ocala

+352 448 7797

http://www.aimimmuno.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+1.66%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.82%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs